Pioglitazone and Losartan Provides Additional Renoprotection

Not Applicable

Completed

• Conditions: Diabetic Nephropathy; Type 2 Diabetes

• Registration Number: NCT00364988
• Lead Sponsor: Shanghai Jiao Tong University School of Medicine

Brief Summary

Peroxisomal proliferator-activated receptor agonist pioglitazone and rosiglitazone are currently used in the treatment of type 2 diabetes, as efficient insulin sensitizers alone or in combination with insulin.angiotensin II receptor antagonist losartan reduced the levels of proteinuria.Whether Combination therapy with pioglitazone and losartan provides additional renoprotection in subjects with type 2 diabetic nephropathy,it's worth researching.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-01
• Primary Completion: 2005-12
• Study Completion: 2006-01
• Study First Submitted: 2006-08-14
• Study First Submitted QC: 2006-08-14
• Study First Posted: 2006-08-16
• Status Verified: 2014-10
• Last Update Submitted: 2014-10-23
• Last Update Posted: 2014-10-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Fasting plasma glucose (FPG) level of 3.3-9.0mmol/L
• 2h plasma glucose level of 7.5-13 mmol/L
• serum creatinine values between 190 and 660umol/L
• Two occasions of a ratio of urinary albumin to urinary creatinine≥300 or 24 hours urinary protein concentration is >150mg
• Informed consent

Exclusion Criteria

• Type1 diabetes or nondiabetic renal disease
• abnormal liver function
• heart dysfunction

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Renal function	12 month	fasting glucose, HbA 1c , Scr, 24-hour urinary protein excretion, and endogenous creatinine clearance (Ccr)